Press release
Parkinson's disease psychosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Vanda Pharmaceuticals, Sumitomo Pharma
Parkinson's disease psychosis Pipeline Insights, DelveInsight
Parkinson's disease psychosis Overview:
Nonmotor symptoms significantly affect the quality of life of both Parkinson's disease (PD) patients and their caregivers, and an increasing number of healthcare professionals recognize their impact. Psychosis is one of the most prevalent and debilitating nonmotor symptoms in PD, occurring in 20% to 70% of patients in advanced stages. It typically develops in individuals with a clear sensorium in a chronic setting after prolonged disease progression and is often triggered or worsened by medication. However, recent studies have identified additional risk factors, suggesting a multifactorial cause and complex underlying pathophysiology. The distinction between early and late-onset psychosis, both generally and in PD specifically, remains unvalidated, with some studies arbitrarily defining early-onset psychosis as occurring within 2-4 years of PD diagnosis.
Request for a detailed insights report on Parkinson's disease psychosis pipeline insights @ https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Parkinson's disease psychosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's disease psychosis Therapeutics Market.
Key Takeaways from the Parkinson's disease psychosis Pipeline Report
DelveInsight's Parkinson's disease psychosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Parkinson's disease psychosis treatment.
Key Parkinson's disease psychosis companies such as Vanda Pharmaceuticals, Sumitomo Pharma, and others are evaluating new drugs for Parkinson's disease psychosis to improve the treatment landscape.
Promising Parkinson's disease psychosis pipeline therapies in various stages of development include Iloperidone, Ulotaront, and others.
Recent breakthroughs in the Parkinson's disease psychosis Pipeline Segment:
AbbVie Inc. has been developing tavapadon, a selective D1/D5 receptor partial agonist, for early-stage Parkinson's disease. In December 2025, AbbVie announced positive results from a third Phase 3 trial, demonstrating significant improvements in motor function. The company plans to seek FDA approval in 2025.
Parkinson's disease psychosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Parkinson's disease psychosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's disease psychosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson's disease psychosis market.
Download our free sample page report on Parkinson's disease psychosis pipeline insights @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Parkinson's disease psychosis Emerging Drugs
Iloperidone: Vanda Pharmaceuticals
Ulotaront: Sumitomo Pharma
Parkinson's disease psychosis Companies
Around five or more key companies are actively developing therapies for Parkinson's disease psychosis. Among them, Vanda Pharmaceuticals has a drug candidate in the most advanced stage of development, specifically in Phase II clinical trials.
DelveInsight's report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Parkinson's disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Parkinson's disease psychosis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's disease psychosis Therapies and Key Companies: Parkinson's disease psychosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Parkinson's disease psychosis Pipeline Therapeutic Assessment
• Parkinson's disease psychosis Assessment by Product Type
• Parkinson's disease psychosis By Stage
• Parkinson's disease psychosis Assessment by Route of Administration
• Parkinson's disease psychosis Assessment by Molecule Type
Download Parkinson's disease psychosis Sample report to know in detail about the Parkinson's disease psychosis treatment market @ Parkinson's disease psychosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Parkinson's disease psychosis Current Treatment Patterns
4. Parkinson's disease psychosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson's disease psychosis Late-Stage Products (Phase-III)
7. Parkinson's disease psychosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson's disease psychosis Discontinued Products
13. Parkinson's disease psychosis Product Profiles
14. Parkinson's disease psychosis Key Companies
15. Parkinson's disease psychosis Key Products
16. Dormant and Discontinued Products
17. Parkinson's disease psychosis Unmet Needs
18. Parkinson's disease psychosis Future Perspectives
19. Parkinson's disease psychosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parkinson's disease psychosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's disease psychosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Vanda Pharmaceuticals, Sumitomo Pharma here
News-ID: 3933750 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
